Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NK Cells and Anti-GD2 for Neuroblastoma
NCT03242603Phase 2Unknown
- Sponsor
- National University Hospital
- Start
- Oct 2017
- Primary completion
- Aug 2019
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of haploidentical natural killer cells in neuroblastoma, sponsored by National University Hospital. Primary endpoint: Tumor response after infusion at 2 years. Status: unknown.
02
Drugs
haploidentical natural killer cells
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT03242603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03242603.